{"id":"glimepiride-metformin-fixed-combination","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Hypoglycemia"},{"rate":"10-20","effect":"Gastrointestinal disturbance (nausea, diarrhea, abdominal discomfort)"},{"rate":"5-10","effect":"Headache"},{"rate":"3-8","effect":"Dizziness"},{"rate":"2-5","effect":"Weight gain"}]},"_chembl":{"chemblId":"CHEMBL1481","moleculeType":"Small molecule","molecularWeight":"490.63"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Glimepiride is a meglitinide that binds to ATP-sensitive potassium channels on beta cells, triggering insulin release in response to glucose. Metformin is a biguanide that reduces hepatic gluconeogenesis and improves peripheral insulin sensitivity without stimulating insulin secretion. Together, they provide complementary glucose-lowering effects through different mechanisms.","oneSentence":"This combination reduces blood glucose by stimulating insulin secretion from pancreatic beta cells (glimepiride) and decreasing hepatic glucose production while improving insulin sensitivity (metformin).","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:47:07.678Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT06759922","phase":"PHASE4","title":"Glimepiride, Empagliflozin, and Sitagliptin With Metformin for Type 2 Diabetes","status":"COMPLETED","sponsor":"Bahria University","startDate":"2025-01-01","conditions":"Type 2 Diabetes Mellitus","enrollment":172},{"nctId":"NCT02395237","phase":"PHASE1","title":"COMPOUND (INN): HOE490O - GLIMEPIRIDE / METFORMIN HCl (Amaryl® M)0 (Glimepiride/Metformin Hydrochloride Immediate Release Combination Tablet) in Fed Conditions in Healthy Male and/or Female Subjects.","status":"WITHDRAWN","sponsor":"Pharmaceutical Research Unit, Jordan","startDate":"2015-05","conditions":"Healthy","enrollment":""},{"nctId":"NCT01678820","phase":"PHASE3","title":"A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-10","conditions":"Type 2 Diabetes Mellitus","enrollment":299},{"nctId":"NCT00993187","phase":"PHASE4","title":"Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-05-04","conditions":"Type 2 Diabetes Mellitus","enrollment":292},{"nctId":"NCT01561976","phase":"NA","title":"Evaluation of Food Effect on the Pharmacokinetics of Sustained Release Metformin in Healthy Indian Volunteers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-01-30","conditions":"Diabetes Mellitus, Type 2","enrollment":30},{"nctId":"NCT01725672","phase":"PHASE1","title":"Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Extended Release Metformin and Extended Release Glimepiride in Health Volunteers","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2012-09-27","conditions":"Diabetes Mellitus, Type 2","enrollment":20},{"nctId":"NCT01699932","phase":"PHASE3","title":"Efficacy and Safety of the Fixed Dose Combination of Glimepiride+Metformin in Type 2 Diabetic Patients Inadequately Controlled","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-09","conditions":"Type 2 Diabetes Mellitus","enrollment":167},{"nctId":"NCT01457911","phase":"PHASE3","title":"Evaluation of Fixed Dose Combination of Glimepiride and Metformin in Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-10","conditions":"Type 2 Diabetes Mellitus","enrollment":244},{"nctId":"NCT00612144","phase":"PHASE4","title":"Study Comparing Efficacy and Safety of Amaryl M and Metformin Uptitraion to Type 2 DM","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2007-12","conditions":"Type 2 Diabetes Mellitus","enrollment":192},{"nctId":"NCT00913367","phase":"PHASE4","title":"Efficacy/Safety Study of Amaryl®M 1/500 mg Twice Daily Versus Amaryl® 4 mg Both in Combination With Lantus® in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2009-05","conditions":"Type 2 Diabetes Mellitus","enrollment":110},{"nctId":"NCT01444248","phase":"PHASE4","title":"Compare the Compliance of Patients Treated With Once-daily (od) or Twice-daily (Bid) Glimepiride and Metformin Fixed Combination Therapy","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2010-08","conditions":"Type 2 Diabetes Mellitus","enrollment":168},{"nctId":"NCT01204580","phase":"PHASE4","title":"ADIponectin and Asymmetric Dimethylarginine (ADMA) Level in Type-2 Diabetes Patients After 12 Weeks of Treatment With GlimepiRide And Metformin Fixed Dose Combination","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-12","conditions":"Diabetes Mellitus, Type 2","enrollment":40},{"nctId":"NCT01144728","phase":"PHASE4","title":"Initiation and Titration of Amaryl","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-05","conditions":"Diabetes Mellitus, Type 2","enrollment":172},{"nctId":"NCT00770653","phase":"PHASE3","title":"Efficacy of Pioglitazone/Metformin Combination Therapy in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia.","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-04","conditions":"Diabetes Mellitus, Dyslipidemias","enrollment":305},{"nctId":"NCT00934817","phase":"PHASE1","title":"Dose Proportionality Study Comparing Amaryl-M 1/500 mg and Amaryl-M 2/500 mg","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2007-03","conditions":"Healthy","enrollment":36},{"nctId":"NCT00934323","phase":"PHASE1","title":"Dose Proportionality Study About Amaryl M Slow Release (SR) 1/500 mg","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2008-10","conditions":"Healthy","enrollment":33},{"nctId":"NCT00318656","phase":"PHASE4","title":"24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-11","conditions":"Non-Insulin-Dependent Diabetes Mellitus","enrollment":23}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Amaryl M"],"phase":"marketed","status":"active","brandName":"Glimepiride/metformin fixed combination","genericName":"Glimepiride/metformin fixed combination","companyName":"Handok Inc.","companyId":"handok-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination reduces blood glucose by stimulating insulin secretion from pancreatic beta cells (glimepiride) and decreasing hepatic glucose production while improving insulin sensitivity (metformin). Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}